


Asia's Top 30 Companies Defining the Next Era of Peptide Therapeutics


*From blockbuster metabolic medicines
to oncology, rare diseases, precision
delivery and next-generation conjugates*

ASIA'S PEPTIDE INNOVATION HUBS



Hub colour key used throughout this report: ● Japan ● South Korea ● China

KEY TRENDS SHAPING THE NEXT ERA OF PEPTIDE THERAPEUTICS



"Peptide therapeutics are having a moment, but the story is no longer just about GLP-1."

This report highlights 30 companies shaping where the peptide therapeutics industry goes next.

BEYOND GLP-1

The commercial success of metabolic peptide medicines has brought unprecedented attention to the modality. At the same time, a broader wave of innovation is emerging across oncology, cardiovascular disease, endocrinology, immunology, rare diseases, and precision medicine.

From oral peptides and long-acting formulations to macrocyclic peptides, peptide-oligonucleotide conjugates and AI-enabled discovery platforms, the next generation of peptide medicines is beginning to look very different.

This report highlights 30 companies shaping where the peptide therapeutics industry goes next.

CHALLENGES THE INDUSTRY IS NOW SOLVING

- Short half-life
- Poor bioavailability
- Limited tissue targeting
- Complex manufacturing

A BROADER WAVE OF INNOVATION ACROSS

- Oncology
- Cardiovascular
- Endocrinology
- Immunology
- Rare diseases
- Precision medicine

INSIDE THIS REPORT · 30 COMPANIES BY INNOVATION HUB

JAPAN

12 COMPANIES

- PeptiDream
- Takeda
- Chugai Pharmaceutical
- Astellas Pharma
- Daiichi Sankyo
- Ono Pharmaceutical
- Asahi Kasei Pharma
- Otsuka Pharmaceutical
- Sumitomo Pharma
- Kyowa Kirin
- Mitsubishi Tanabe Pharma
- JITSUBO

See page 04 →

SOUTH KOREA

8 COMPANIES

- Hanmi Pharmaceutical
- Pepton
- HanAll Biopharma
- Dong-A ST
- LG Chem Life Sciences
- Daewoong Pharmaceutical
- OliX Pharmaceuticals
- ST Pharm

See page 05 →

CHINA

10 COMPANIES

- Hengrui Pharmaceuticals
- Innovent Biologics
- Hansoh Pharmaceutical
- CSPC Pharmaceutical Group
- Akeso
- Luye Pharma Group
- China Medical System
- Hengrui / Kailera Therapeutics
- Sirnaomics
- GL Biochem

See page 06 →

JAPAN

12 companies

Established pharma leaders and peptide-discovery specialists driving macrocyclic, precision and conjugate innovation.



PeptiDream

● Japan

WHY THEY MATTER

Global leader in macrocyclic peptide discovery.

WHAT TO WATCH

Macrocyclic, oral peptides and conjugates.



Takeda

● Japan

WHY THEY MATTER

Global innovator with broad advanced-modality expertise.

WHAT TO WATCH

Next-generation peptide discovery opportunities.



Chugai Pharmaceutical

● Japan

WHY THEY MATTER

Leader in advanced drug discovery and molecular engineering.

WHAT TO WATCH

Precision therapeutics and novel platforms.



Astellas Pharma

● Japan

WHY THEY MATTER

Global pharma expands into advanced modalities.

WHAT TO WATCH

Novel platforms for difficult targets.



Daiichi Sankyo

● Japan

WHY THEY MATTER

Leader in targeted and conjugated therapeutics.

WHAT TO WATCH

Peptide targeting and precision delivery.



Ono Pharmaceutical

● Japan

WHY THEY MATTER

Major innovators across oncology and specialty diseases.

WHAT TO WATCH

Targeted peptide medicines and new modalities.



Asahi Kasei Pharma

● Japan

WHY THEY MATTER

Established innovator in specialty medicines.

WHAT TO WATCH

New discovery technologies and differentiated therapies.



Otsuka Pharmaceutical

● Japan

WHY THEY MATTER

Global innovator specialty and complex medicines.

WHAT TO WATCH

Precision medicine and new modalities.



Sumitomo Pharma

● Japan

WHY THEY MATTER

Innovator across neuroscience and oncology.

WHAT TO WATCH

Advanced discovery for difficult targets.



Kyowa Kirin

● Japan

WHY THEY MATTER

Specialist in targeted and rare disease therapies.

WHAT TO WATCH

Precision technologies and rare diseases.



Mitsubishi Tanabe Pharma

● Japan

WHY THEY MATTER

Established player in metabolic and specialty diseases.

WHAT TO WATCH

Peptide opportunities in chronic diseases.



JITSUBO

● Japan

WHY THEY MATTER

Specialist in peptide synthesis technologies.

WHAT TO WATCH

Linear, cyclic, and modified peptides.



SOUTH KOREA

8 companies

Long-acting technologies, sustained-release delivery and complex-modality manufacturing expertise.



Hanmi Pharmaceutical

South Korea

WHY THEY MATTER

Leader in long-acting peptide technologies.

WHAT TO WATCH

GLP-1, multi-agonists, and metabolic peptides.



Peptron

South Korea

WHY THEY MATTER

Specialist in sustained-release drug delivery.

WHAT TO WATCH

Long-acting peptides and depot technologies.



HanAll Biopharma

South Korea

WHY THEY MATTER

Biopharma invests in differentiated drug platforms.

WHAT TO WATCH

New therapeutic technologies and complex modalities.



Dong-A ST

South Korea

WHY THEY MATTER

Established innovator expanding its R&D pipeline.

WHAT TO WATCH

Partnerships and next-generation medicines.



LG Chem Life Sciences

South Korea

WHY THEY MATTER

Major player with broad drug development capabilities.

WHAT TO WATCH

Metabolic, oncology, and innovative therapies.



Daewoong Pharmaceutical

South Korea

WHY THEY MATTER

Major Korean pharma focused on R&D-driven medicines.

WHAT TO WATCH

Novel biologics and advanced modalities.



OliX Pharmaceuticals

South Korea

WHY THEY MATTER

Leading RNA therapeutics company with delivery expertise.

WHAT TO WATCH

RNA delivery and targeting technologies.



ST Pharm

South Korea

WHY THEY MATTER

Key Asian manufacturer of complex modalities.

WHAT TO WATCH

Oligonucleotide and peptide convergence.



CHINA

10 companies

Fast-moving metabolic pipelines, GLP-1 multi-agonists and AI-enabled discovery, increasingly going global.

**Hengrui Pharmaceuticals****WHY THEY MATTER**

Major innovator expanding metabolic therapeutics.

WHAT TO WATCH

GLP-1/GIP and next-gen metabolic pipeline.

**Innovent Biologics****WHY THEY MATTER**

Fast growing biopharma in metabolic innovation.

WHAT TO WATCH

Mazdutide and multi-target peptide therapies.

**Hansoh Pharmaceutical****WHY THEY MATTER**

Emerging player in metabolic therapeutics.

WHAT TO WATCH

GLP-1/GIP dual agonist programmes.

**CSPC Pharmaceutical Group****WHY THEY MATTER**

Pharma giant investing in peptides and AI discovery.

WHAT TO WATCH

Long-acting incretins and AI-driven discovery.

**Akeso****WHY THEY MATTER**

Fast-growing biopharma expanding in innovative medicines.

WHAT TO WATCH

Multi-target approaches and novel combinations.

**Luye Pharma Group****WHY THEY MATTER**

Major pharma with expertise in long-acting formulations.

WHAT TO WATCH

Long-acting delivery and complex formulations.

**China Medical System****WHY THEY MATTER**

Building an innovative metabolic therapeutics pipeline.

WHAT TO WATCH

GLP-1/glucagon dual agonists.

**Hengrui / Kailera Therapeutics****WHY THEY MATTER**

Illustrates globalization of Asian metabolic assets.

WHAT TO WATCH

International development of GLP-1 assets.

**Sirnaomics****WHY THEY MATTER**

Asia-based RNA therapeutics developer with advanced delivery platforms.

WHAT TO WATCH

Targeted RNA delivery strategies.

**GL Biochem****WHY THEY MATTER**

Major specialist in peptide research and synthesis.

WHAT TO WATCH

Advanced synthesis for next-gen peptides.

— ABOUT THE CONGRESS

OLIGONUCLEOTIDES & PEPTIDES WORLD ASIA CONGRESS 2027

2nd Edition · 23–24 March 2027 · Sands Expo & Convention Centre, Marina Bay Sands, Singapore

The Oligonucleotides & Peptides World Asia Congress 2027 brings together leaders working across the full development lifecycle of next-generation therapeutics.

KEY TOPICS INCLUDE

-  RNA and oligonucleotide innovation
-  Peptide therapeutics beyond metabolic disease
-  Precision delivery and tissue targeting
-  Oligonucleotide-peptide conjugates
-  Antibody-peptide and radionuclide drug conjugates
-  Clinical development and regulatory strategy
-  Manufacturing, CMC and commercial scale-up
-  Analytical innovation and quality
-  The convergence of next-generation therapeutic modalities

JOIN THE INDUSTRY LEADERS BUILDING WHAT COMES NEXT.

REGISTER NOW →

www.imapac.com/events/oligonucleotides-peptides-world-asia-congress-2027